Tokyo Tape
Sign in
← Medinet

Quarterly report · Q2

2370.TEDINET S100QQH6
Period2022-10-01 → 2023-03-31
Filed2023-05-12
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥349m2022-10-01 → 2023-03-31StandaloneNet sales
Revenue¥634m2021-10-01 → 2022-09-30StandaloneNet sales (5-year summary)
Revenue¥318m2021-10-01 → 2022-03-31StandaloneNet sales
Operating income−¥672m2022-10-01 → 2023-03-31StandaloneOperating income
Operating income−¥678m2021-10-01 → 2022-03-31StandaloneOperating income
Ordinary income−¥670m2022-10-01 → 2023-03-31StandaloneOrdinary income
Ordinary income−¥1.3bn2021-10-01 → 2022-09-30StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥676m2021-10-01 → 2022-03-31StandaloneOrdinary income
Profit before tax−¥674m2022-10-01 → 2023-03-31StandaloneIncome before income taxes
Profit before tax−¥676m2021-10-01 → 2022-03-31StandaloneIncome before income taxes
Net income−¥677m2022-10-01 → 2023-03-31StandaloneProfit loss
Net income−¥1.3bn2021-10-01 → 2022-09-30StandaloneNet income loss (5-year summary)
Net income−¥679m2021-10-01 → 2022-03-31StandaloneProfit loss
Total assets¥5.4bnat 2023-03-31StandaloneAssets
Total assets¥6.1bnat 2022-09-30StandaloneAssets
Total assets¥6.3bnat 2022-03-31StandaloneTotal assets (5-year summary)
Total liabilities¥529mat 2023-03-31StandaloneLiabilities
Total liabilities¥566mat 2022-09-30StandaloneLiabilities
Net assets / equity¥4.9bnat 2023-03-31StandaloneNet assets
Net assets / equity¥5.5bnat 2022-09-30StandaloneNet assets
Net assets / equity¥5.6bnat 2022-03-31StandaloneNet assets (5-year summary)
Cash and deposits¥4.0bnat 2023-03-31StandaloneCash and deposits
Cash and deposits¥4.5bnat 2022-09-30StandaloneCash and deposits
Cash & equivalents¥4.0bnat 2023-03-31StandaloneCash and cash equivalents
Cash & equivalents¥4.5bnat 2022-09-30StandaloneCash and cash equivalents
Cash & equivalents¥4.3bnat 2022-03-31StandaloneCash and cash equivalents
Cash & equivalents¥4.1bnat 2021-09-30dStandaloneCash and cash equivalents
Operating cash flow−¥564m2022-10-01 → 2023-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.2bn2021-10-01 → 2022-09-30StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥612m2021-10-01 → 2022-03-31StandaloneNet cash provided by used in operating activities
Investing cash flow−¥35m2022-10-01 → 2023-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥20m2021-10-01 → 2022-09-30StandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥23m2021-10-01 → 2022-03-31StandaloneNet cash provided by used in investment activities
Financing cash flow¥133m2022-10-01 → 2023-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.6bn2021-10-01 → 2022-09-30StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥885m2021-10-01 → 2022-03-31StandaloneNet cash provided by used in financing activities
EPS (basic)¥-3.192022-10-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-1.662023-01-01 → 2023-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.332021-10-01 → 2022-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-3.632021-10-01 → 2022-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-1.752022-01-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
Equity ratio89.6%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio90.7%at 2022-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio89.3%at 2022-03-31StandaloneEquity to asset ratio (5-year summary)
Shares issued213,465,757at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued211,730,423at 2022-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued197,000,423at 2022-03-31StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2023-03-31−¥313m
jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segmentrevenue2022-10-01 → 2023-03-31¥276,000
jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segmentrevenue external2022-10-01 → 2023-03-31¥276,000
jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segmentsegment profit2022-10-01 → 2023-03-31−¥225m
jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segmentrevenue2022-10-01 → 2023-03-31¥349m
jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segmentrevenue external2022-10-01 → 2023-03-31¥349m
jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segmentsegment profit2022-10-01 → 2023-03-31−¥133m
—segment totalrevenue2022-10-01 → 2023-03-31¥349m
—segment totalrevenue external2022-10-01 → 2023-03-31¥349m
—segment totalsegment profit2022-10-01 → 2023-03-31−¥358m
Reconciling Itemsreconcilingsegment profit2021-10-01 → 2022-03-31−¥265m
jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segmentrevenue2021-10-01 → 2022-03-31¥69,000
jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segmentrevenue external2021-10-01 → 2022-03-31¥69,000
jpcrp040300-q2r_E05351-000Cellular And Tissue Based Product Businessreportable segmentsegment profit2021-10-01 → 2022-03-31−¥308m
jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segmentrevenue2021-10-01 → 2022-03-31¥318m
jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segmentrevenue external2021-10-01 → 2022-03-31¥318m
jpcrp040300-q2r_E05351-000Contract Cell Manufacturing Businessreportable segmentsegment profit2021-10-01 → 2022-03-31−¥105m
—segment totalrevenue2021-10-01 → 2022-03-31¥318m
—segment totalrevenue external2021-10-01 → 2022-03-31¥318m
—segment totalsegment profit2021-10-01 → 2022-03-31−¥413m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 461
ItemContextValueUnit
Effect of exchange rate change on cash and cash equivalentsCurrentYTDDuration_NonConsolidatedMember-0JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration_NonConsolidatedMember249100000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration_NonConsolidatedMember-465375000JPY
Cash and cash equivalentsPrior2YearInstant_NonConsolidatedMember4095689000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember4499095000JPY
Cash and cash equivalentsPrior1QuarterInstant_NonConsolidatedMember4344790000JPY
Cash and cash equivalentsCurrentQuarterInstant_NonConsolidatedMember4033720000JPY
Provision for bonuses sgaPrior1YTDDuration_NonConsolidatedMember21007000JPY
Provision for bonuses sgaCurrentYTDDuration_NonConsolidatedMember26275000JPY
Provision for share based payments sgaPrior1YTDDuration_NonConsolidatedMember－JPY
Provision for share based payments sgaCurrentYTDDuration_NonConsolidatedMember2847000JPY
Research and development expenses sgaPrior1YTDDuration_NonConsolidatedMember295705000JPY
Research and development expenses sgaCurrentYTDDuration_NonConsolidatedMember226268000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember318019000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember69000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember318089000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember318089000JPY
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember－JPY
Net salesPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember318019000JPY
Net salesPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember69000JPY
Net salesPrior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember318089000JPY
Net salesPrior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesPrior1YTDDuration_NonConsolidatedMember318089000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember-105453000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember-307530000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember-412983000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember-265310000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember-678294000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember349137000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember276000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember349413000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember349413000JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember－JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember349137000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember276000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember349413000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesCurrentYTDDuration_NonConsolidatedMember349413000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember-133163000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember-225251000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2022-09-30pass rounding
balance sheet identitynon_consolidated 2023-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-09-30pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · operating cash flownon_consolidated 2021-10-01/2022-03-31pass
statement vs summary · operating cash flownon_consolidated 2022-10-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2021-10-01/2022-03-31pass
statement vs summary · revenuenon_consolidated 2022-10-01/2023-03-31pass
statement vs summary · total assetsnon_consolidated 2022-09-30pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass